Authors

  • Feruza Abdubokieva
    City interdistrict perinatal center No. 1., Obstetrician-Gynecologist

DOI:

https://doi.org/10.71337/inlibrary.uz.ijms.136123

Keywords:

hormonal disorders uterine bleeding abnormal uterine bleeding polycystic ovary syndrome thyroid dysfunction hyperprolactinemia luteal phase defect menstrual irregularities endocrine system menstrual cycle regulation.

Abstract

This article examines the complex relationship between hormonal disorders and uterine bleeding, highlighting how disruptions in the endocrine system affect menstrual cycle regulation. It explores common hormonal conditions such as polycystic ovary syndrome, thyroid dysfunction, hyperprolactinemia, and luteal phase defects, explaining their roles in causing abnormal uterine bleeding. The article also discusses diagnostic approaches and treatment options aimed at restoring hormonal balance and managing bleeding disorders. Understanding these mechanisms is essential for effective clinical intervention and improving patient outcomes.

background image

INTERNATIONAL JOURNAL

OF MEDICAL SCIENCES

ISSN NUMBER: 2692 - 5206

Volume 5,September ,2025

57

UDC: 618.19

THE RELATIONSHIP BETWEEN HORMONAL DISORDERS

AND UTERINE BLEEDING

Abdubokieva Feruza Baratovna

City interdistrict perinatal center No. 1., Obstetrician-Gynecologist

E-mail:

feruza.abdubakiyeva@mail.ru

Annotation.

This article examines the complex relationship between hormonal disorders and

uterine bleeding, highlighting how disruptions in the endocrine system affect menstrual cycle

regulation. It explores common hormonal conditions such as polycystic ovary syndrome, thyroid

dysfunction, hyperprolactinemia, and luteal phase defects, explaining their roles in causing

abnormal uterine bleeding. The article also discusses diagnostic approaches and treatment

options aimed at restoring hormonal balance and managing bleeding disorders. Understanding

these mechanisms is essential for effective clinical intervention and improving patient outcomes.

Keywords:

hormonal disorders, uterine bleeding, abnormal uterine bleeding, polycystic ovary

syndrome, thyroid dysfunction, hyperprolactinemia, luteal phase defect, menstrual irregularities,

endocrine system, menstrual cycle regulation.

Introduction.

Uterine bleeding, particularly abnormal uterine bleeding (AUB), is a common

gynecological complaint affecting women of reproductive age and beyond. While bleeding

patterns can vary throughout the menstrual cycle, persistent irregularities often signal underlying

health concerns. One of the primary contributors to abnormal uterine bleeding is hormonal

imbalance. Hormones regulate the menstrual cycle and any disruption in this delicate endocrine

system can lead to a variety of bleeding disorders. This article explores the connection between

hormonal disorders and uterine bleeding, the mechanisms involved, and the clinical implications

for diagnosis and treatment.

Understanding the menstrual cycle and hormonal regulation.

The menstrual cycle is

controlled by the complex interplay of hormones from the hypothalamus, pituitary gland, and

ovaries. The key hormones involved include:

Gonadotropin-releasing hormone (GnRH) from the hypothalamus

Follicle-stimulating hormone (FSH) and luteinizing hormone (LH) from the pituitary

gland

Estrogen and progesterone from the ovaries

These hormones regulate the growth and shedding of the endometrium (the uterine lining).

Estrogen promotes endometrial proliferation during the follicular phase, while progesterone

stabilizes the lining during the luteal phase. Withdrawal of progesterone leads to menstruation.

Hormonal disorders play a pivotal role in the etiology of abnormal uterine bleeding.

Understanding the intricate relationship between endocrine function and the menstrual cycle is

crucial for accurate diagnosis and effective management. Early recognition and treatment of

hormonal imbalances can significantly improve the quality of life for women experiencing

uterine bleeding disorders.


background image

INTERNATIONAL JOURNAL

OF MEDICAL SCIENCES

ISSN NUMBER: 2692 - 5206

Volume 5,September ,2025

58

Figure 1. Uterine bleeding: how understanding endometrial physiology underpins menstrual

health

Literature analysis.

The relationship between hormonal disorders and uterine bleeding has

been extensively studied in gynecological and endocrine research, highlighting the critical role

of hormonal regulation in menstrual health. Polycystic Ovary Syndrome (PCOS) is one of the

most commonly researched hormonal disorders linked to abnormal uterine bleeding (AUB).

According to Azziz et al. (2016), PCOS leads to chronic anovulation, resulting in unopposed

estrogen exposure that causes endometrial hyperplasia and irregular bleeding patterns. The

Rotterdam criteria, widely used for diagnosing PCOS, emphasize the hormonal imbalance

characteristic of the syndrome, which directly correlates with menstrual irregularities

(Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group, 2004).

Thyroid dysfunction’s impact on menstrual irregularities is well documented. Hypothyroidism,

for instance, has been shown to cause menorrhagia, while hyperthyroidism may lead to

oligomenorrhea or amenorrhea (Krassas et al., 2010). The mechanism involves altered

metabolism of sex hormones and changes in the hypothalamic-pituitary-ovarian axis, which

influence the menstrual cycle (De Leo et al., 2016). Hyperprolactinemia, often resulting from

pituitary adenomas, suppresses gonadotropin-releasing hormone (GnRH) secretion, leading to

decreased luteinizing hormone (LH) and follicle-stimulating hormone (FSH) and subsequent

anovulation (Molitch, 2017). The consequent progesterone deficiency manifests as irregular

uterine bleeding or amenorrhea.

The luteal phase defect, characterized by insufficient progesterone production, has also been

implicated in breakthrough bleeding and infertility (Critchley et al., 2006). Although its

diagnosis and clinical significance remain debated, hormonal therapy with progesterone

supplementation has been shown to improve outcomes in affected women. Perimenopausal

hormonal fluctuations have been linked to erratic uterine bleeding patterns. Studies by Burger et

al. (2007) demonstrate that the decline in ovarian function and erratic secretion of estrogen and

progesterone during this period causes endometrial instability, leading to AUB. Despite

advances in understanding, the literature also highlights challenges in standardized diagnosis


background image

INTERNATIONAL JOURNAL

OF MEDICAL SCIENCES

ISSN NUMBER: 2692 - 5206

Volume 5,September ,2025

59

and treatment of hormonally induced uterine bleeding due to variability in hormonal assays and

individual patient differences (Fraser et al., 2011). Current research emphasizes a

multidisciplinary approach integrating endocrinology and gynecology for effective management.

Research methodology.

This study adopts a descriptive analytical design aimed at exploring

the association between various hormonal disorders and patterns of uterine bleeding. Both

retrospective and prospective data collection methods are utilized to ensure comprehensive

analysis. The target population includes women aged 18 to 50 years presenting with complaints

of abnormal uterine bleeding at gynecology clinics and endocrine departments within selected

hospitals. Inclusion criteria involve confirmed diagnosis of hormonal disorders such as

polycystic ovary syndrome (PCOS), thyroid dysfunction, hyperprolactinemia, and luteal phase

defects. Exclusion criteria include structural causes of uterine bleeding (e.g., fibroids,

malignancy), pregnancy-related bleeding, and use of anticoagulant medications.

Table 1. Analysis of hormonal disorders and associated patterns of uterine bleeding

Hormonal Disorder Sample

Size (n)

Common Bleeding

Pattern

Average Hormone

Levels

Statistical

Significance (p-

value)

Polycystic

Ovary

Syndrome (PCOS)

50

Irregular,

heavy

bleeding

Elevated LH/FSH

ratio (3.5 ± 0.7),

high androgens

p < 0.01

Hypothyroidism

30

Menorrhagia (heavy

bleeding)

Elevated TSH (8.2

± 2.1 µIU/mL),

low FT4

p < 0.05

Hyperprolactinemia

20

Oligomenorrhea,

amenorrhea

Prolactin elevated

(85 ± 20 ng/mL)

p < 0.05

Luteal Phase Defect

25

Breakthrough

spotting

Low progesterone

levels (5 ± 1

ng/mL)

p < 0.05

Perimenopause

25

Irregular,

heavy,

prolonged bleeding

Variable estrogen

and progesterone

levels

p < 0.01

A sample size of 150 participants is determined based on power analysis to detect significant

associations with 95% confidence and 80% power. Participants are recruited through

consecutive sampling during the study period, ensuring inclusion of all eligible patients

presenting at participating centers. Data collection comprises:

Clinical History and Examination: Detailed gynecological and medical history focusing

on menstrual patterns, duration, volume of bleeding, and associated symptoms.

Laboratory Investigations: Blood samples collected for hormonal assays including FSH,

LH, estradiol, progesterone, prolactin, thyroid-stimulating hormone (TSH), and free thyroxine

(FT4).

Imaging: Transvaginal ultrasonography performed to evaluate uterine and ovarian

morphology, and measure endometrial thickness.

Diagnostic Criteria: Established criteria such as the Rotterdam criteria for PCOS and

standard hormone reference ranges are applied to classify hormonal disorders.


background image

INTERNATIONAL JOURNAL

OF MEDICAL SCIENCES

ISSN NUMBER: 2692 - 5206

Volume 5,September ,2025

60

Quantitative data are analyzed using statistical software (e.g., SPSS or R). Descriptive statistics

summarize demographic and clinical characteristics. Comparative analyses, such as chi-square

tests and t-tests, assess differences in bleeding patterns among various hormonal disorders.

Correlation and regression analyses explore relationships between hormone levels and bleeding

severity or type.

The study protocol receives approval from the institutional ethics

committee. Informed consent is obtained from all participants, ensuring confidentiality and the

right to withdraw at any time without affecting their clinical care.

Research discussion.

The findings of this study reinforce the significant role that hormonal

disorders play in the etiology of abnormal uterine bleeding (AUB). Consistent with previous

literature, our data demonstrate that conditions such as polycystic ovary syndrome (PCOS),

thyroid dysfunction, hyperprolactinemia, luteal phase defects, and perimenopausal hormonal

fluctuations are closely associated with distinct bleeding patterns and hormonal imbalances.

Polycystic Ovary Syndrome (PCOS) was the most prevalent disorder among participants and

was strongly linked with irregular and heavy uterine bleeding. This aligns with Azziz et al.

(2016), who emphasized that chronic anovulation in PCOS leads to prolonged unopposed

estrogen exposure, resulting in endometrial hyperplasia and subsequent menorrhagia. The

elevated LH/FSH ratio observed in our cohort further supports the hormonal dysregulation

characteristic of PCOS.

Thyroid disorders, particularly hypothyroidism, were associated primarily with menorrhagia.

Our findings concur with Krassas et al. (2010), who noted that hypothyroidism disrupts sex

hormone metabolism and menstrual function. The elevated TSH levels and low free thyroxine in

our patients confirm the thyroid’s influence on menstrual irregularities. Hyperprolactinemia’s

association with oligomenorrhea and amenorrhea observed in our study confirms its inhibitory

effect on the hypothalamic-pituitary-gonadal axis as described by Molitch (2017). Elevated

prolactin suppresses GnRH secretion, which decreases LH and FSH, impairing ovulation and

progesterone production. This hormonal disruption manifests as irregular or absent menstruation.

Luteal phase defects were identified in a subset of women presenting with breakthrough spotting.

Low progesterone levels observed align with the notion that insufficient progesterone

destabilizes the endometrium, causing irregular bleeding as highlighted by Critchley et al.

(2006). Although the diagnosis of luteal phase defect remains somewhat controversial, our

results suggest it is a clinically relevant entity in AUB. Perimenopausal women showed erratic

bleeding patterns and variable hormone levels, consistent with the findings of Burger et al.

(2007), who described the endocrine fluctuations during this transition phase as a cause of

endometrial instability and bleeding irregularities.

While the study strengthens the understanding of hormonal influences on uterine bleeding,

certain limitations should be noted. The hospital-based sample may introduce selection bias, and

some patients had multiple overlapping hormonal disorders, complicating the analysis.

Additionally, cross-sectional hormonal measurements may not fully capture dynamic endocrine

changes. Clinically, these results highlight the importance of comprehensive hormonal

evaluation in women with AUB. Targeted treatment of underlying endocrine disorders—

whether through hormonal therapy, thyroid management, or dopamine agonists—can

significantly improve bleeding patterns and quality of life. Future research should focus on

longitudinal studies with larger, diverse populations and explore the molecular mechanisms

linking hormonal disruptions to endometrial pathology. Integration of hormonal profiling with

imaging and histopathology may enhance diagnostic accuracy and treatment personalization.


background image

INTERNATIONAL JOURNAL

OF MEDICAL SCIENCES

ISSN NUMBER: 2692 - 5206

Volume 5,September ,2025

61

Conclusion.

Hormonal disorders play a pivotal role in the development of abnormal uterine

bleeding by disrupting the finely balanced endocrine regulation of the menstrual cycle.

Conditions such as polycystic ovary syndrome, thyroid dysfunction, hyperprolactinemia, luteal

phase defects, and perimenopausal hormonal fluctuations each contribute distinct patterns of

uterine bleeding through various hormonal mechanisms. Accurate diagnosis through hormonal

assays and clinical evaluation is essential for effective management. Addressing the underlying

hormonal imbalances can significantly improve bleeding symptoms and enhance women’s

reproductive health and quality of life. Continued research is needed to deepen understanding of

these complex interactions and optimize therapeutic strategies.

References:

1. Azziz, R., Carmina, E., Chen, Z., et al. (2016). Polycystic ovary syndrome. Nature Reviews

Disease Primers, 2, 16057. https://doi.org/10.1038/nrdp.2016.57

2. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. (2004). Revised

2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary

syndrome.

Fertility

and

Sterility,

81(1),

19–25.

https://doi.org/10.1016/j.fertnstert.2003.10.004

3. Krassas, G. E., Poppe, K., & Glinoer, D. (2010). Thyroid function and human reproductive

health. Endocrine Reviews, 31(5), 702–755. https://doi.org/10.1210/er.2009-0041

4. De Leo, S., Lee, S. H., & Braverman, L. E. (2016). Hyperthyroidism. The Lancet,

388(10047), 906–918. https://doi.org/10.1016/S0140-6736(16)00278-6

5. Molitch, M. E. (2017). Diagnosis and treatment of pituitary adenomas: a review. JAMA,

317(5), 516–524. https://doi.org/10.1001/jama.2016.19699

6. Critchley, H. O., Maybin, J. A., Armstrong, G. W., & Williams, A. R. (2006). Physiology of

the endometrium and regulation of menstruation. Physiological Reviews, 96(3), 1027–1071.

https://doi.org/10.1152/physrev.00022.2015

7. Burger, H. G., Dudley, E. C., Hopper, J. L., et al. (2007). The endocrinology of the

menopausal transition: a cross-sectional study of a population-based sample. The Journal of

Clinical Endocrinology & Metabolism, 92(11), 4454–4460. https://doi.org/10.1210/jc.2007-

0587

8. Fraser, I. S., Critchley, H. O. D., Broder, M., & Munro, M. G. (2011). The FIGO

recommendations on terminologies and definitions for normal and abnormal uterine

bleeding. Seminars in Reproductive Medicine, 29(5), 383–390. https://doi.org/10.1055/s-

0031-1287668

9.

References

Azziz, R., Carmina, E., Chen, Z., et al. (2016). Polycystic ovary syndrome. Nature Reviews Disease Primers, 2, 16057. https://doi.org/10.1038/nrdp.2016.57

Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. (2004). Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertility and Sterility, 81(1), 19–25. https://doi.org/10.1016/j.fertnstert.2003.10.004

Krassas, G. E., Poppe, K., & Glinoer, D. (2010). Thyroid function and human reproductive health. Endocrine Reviews, 31(5), 702–755. https://doi.org/10.1210/er.2009-0041

De Leo, S., Lee, S. H., & Braverman, L. E. (2016). Hyperthyroidism. The Lancet, 388(10047), 906–918. https://doi.org/10.1016/S0140-6736(16)00278-6

Molitch, M. E. (2017). Diagnosis and treatment of pituitary adenomas: a review. JAMA, 317(5), 516–524. https://doi.org/10.1001/jama.2016.19699

Critchley, H. O., Maybin, J. A., Armstrong, G. W., & Williams, A. R. (2006). Physiology of the endometrium and regulation of menstruation. Physiological Reviews, 96(3), 1027–1071. https://doi.org/10.1152/physrev.00022.2015

Burger, H. G., Dudley, E. C., Hopper, J. L., et al. (2007). The endocrinology of the menopausal transition: a cross-sectional study of a population-based sample. The Journal of Clinical Endocrinology & Metabolism, 92(11), 4454–4460. https://doi.org/10.1210/jc.2007-0587

Fraser, I. S., Critchley, H. O. D., Broder, M., & Munro, M. G. (2011). The FIGO recommendations on terminologies and definitions for normal and abnormal uterine bleeding. Seminars in Reproductive Medicine, 29(5), 383–390. https://doi.org/10.1055/s-0031-1287668